FIELD: medicine, ophthalmology, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to a combination of agents used in treatment or prophylaxis of glaucoma. The combination comprises angiotensin II antagonist of the formula (Ia): 
and prostaglandin representing isopropylunoprostone or latanoprost as active components for simultaneous or successive using the indicated active components. The combination shows high effectiveness and bioavailability and has no toxicity.
EFFECT: improved and valuable medicinal properties of combination.
5 cl, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SULFONAMIDE COMPOUND | 2006 |
|
RU2376300C1 |
| INTRACHAMBER IMPLANTS WITH PROLONGED RELEASE OF THERAPEUTIC AGENT | 2011 |
|
RU2565445C2 |
| PHARMACEUTICAL TABLET | 2003 |
|
RU2273473C2 |
| PHARMACEUTICAL DOSED FORMULATION FOR DELIVERY THROUGH MUCOSA | 2003 |
|
RU2285520C2 |
| NEUTRAL ENDOPEPTIDASE (NEP) AND SOLUBLE HUMAN ENDOPEPTIDASE (SHE) INHIBITORS FOR PREVENTION AND TREATMENT OF EYE DISEASES | 2019 |
|
RU2758771C1 |
| REDUCTION OF INTRAOCULAR PRESSURE BY INTRACHAMBER BIMATOPROST IMPLANTS | 2011 |
|
RU2586298C2 |
| PHARMACEUTICAL DRUG CONTAINING PYRIDYLAMINOACETIC ACID | 2018 |
|
RU2776374C2 |
| INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
| CONJUGATES AND PROSTAGLANDIN DERIVATIVES FOR TREATING GLAUCOMA AND INTRAOCULAR HYPERTENSION | 2015 |
|
RU2712221C2 |
| (-AMINO-(-HYDROXY-(-ARYLALKANOIC AMIDES AND USE THEREOF AS RENIN INHIBITORS | 2004 |
|
RU2425027C2 |
